Researchers Create First Chemical Tools to Map the CB1 Receptor's Allosteric Binding Site
Scientists designed and synthesized the first covalent chemical probes capable of permanently binding to the CB1 receptor's allosteric site, with the lead compound GAT100 showing exceptional potency as a negative allosteric modulator.
Quick Facts
What This Study Found
The CB1 receptor has a primary (orthosteric) binding site where THC and most cannabinoid drugs bind, and a secondary (allosteric) site where modulators can fine-tune receptor activity. But the exact location and structure of this allosteric site has been unknown.
This study created the first chemical tools to map this site. Researchers designed covalent probes, compounds that permanently attach to specific amino acids, based on two known allosteric modulators (Org27569 and PSNCBAM-1).
The lead compound, GAT100, emerged as a highly potent negative allosteric modulator that, unlike its parent compounds, did not exhibit inverse agonism (reducing baseline receptor activity). It also enhanced binding of orthosteric agonists. These properties make GAT100 a valuable research tool for understanding allosteric modulation and a potential starting point for drug development.
Key Numbers
GAT100 identified as lead compound from a focused library. Most potent negative allosteric modulator in GTPgammaS and beta-arrestin assays. Reduced inverse agonism compared to Org27569. Positive allosteric modulation of CP55,940 binding.
How They Did This
Medicinal chemistry study involving rational design, synthesis, and pharmacological characterization of covalent CB1 allosteric ligands. Compounds were tested in radioligand binding, GTPgammaS functional assays, and beta-arrestin recruitment assays.
Why This Research Matters
Mapping the CB1 allosteric site is essential for designing next-generation cannabinoid drugs that could modulate the receptor with more precision and fewer side effects than current drugs. GAT100 is the key that could unlock this understanding.
The Bigger Picture
Allosteric modulators represent the next frontier in cannabinoid pharmacology. By developing tools to map exactly where and how these modulators bind, researchers can move from serendipitous discovery to rational drug design for conditions ranging from pain to neurodegeneration.
What This Study Doesn't Tell Us
In vitro study with no in vivo validation. Covalent probes permanently modify the receptor, which limits their therapeutic potential but makes them valuable research tools. The allosteric site structure remains to be fully characterized.
Questions This Raises
- ?Will GAT100 successfully map the allosteric site through structural studies?
- ?Could non-covalent analogs of GAT100 be developed as therapeutic drugs?
- ?What is the three-dimensional structure of the CB1 allosteric site?
Trust & Context
- Key Stat:
- First covalent probes for the CB1 allosteric site, with GAT100 as lead compound
- Evidence Grade:
- Novel medicinal chemistry achievement with thorough pharmacological characterization, but entirely in vitro.
- Study Age:
- Published in 2016. GAT100 and related probes have since been used in further structural and functional studies of the CB1 receptor.
- Original Title:
- Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).
- Published In:
- Journal of medicinal chemistry, 59(1), 44-60 (2016)
- Authors:
- Kulkarni, Pushkar M(3), Kulkarni, Abhijit R(2), Korde, Anisha, Tichkule, Ritesh B, Laprairie, Robert B, Denovan-Wright, Eileen M, Zhou, Han, Janero, David R, Zvonok, Nikolai, Makriyannis, Alexandros, Cascio, Maria G, Pertwee, Roger G, Thakur, Ganesh A
- Database ID:
- RTHC-01201
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is an allosteric site and why does it matter?
It's a secondary binding pocket on the CB1 receptor, separate from where THC binds. Drugs targeting this site could fine-tune receptor activity more precisely than THC or other direct-acting drugs, potentially with fewer side effects.
What makes GAT100 special?
It's the first tool capable of permanently attaching to the CB1 allosteric site, allowing researchers to map its exact location. It also has improved properties compared to previous allosteric modulators, including reduced unwanted inverse agonism.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01201APA
Kulkarni, Pushkar M; Kulkarni, Abhijit R; Korde, Anisha; Tichkule, Ritesh B; Laprairie, Robert B; Denovan-Wright, Eileen M; Zhou, Han; Janero, David R; Zvonok, Nikolai; Makriyannis, Alexandros; Cascio, Maria G; Pertwee, Roger G; Thakur, Ganesh A. (2016). Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).. Journal of medicinal chemistry, 59(1), 44-60. https://doi.org/10.1021/acs.jmedchem.5b01303
MLA
Kulkarni, Pushkar M, et al. "Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).." Journal of medicinal chemistry, 2016. https://doi.org/10.1021/acs.jmedchem.5b01303
RethinkTHC
RethinkTHC Research Database. "Novel Electrophilic and Photoaffinity Covalent Probes for Ma..." RTHC-01201. Retrieved from https://rethinkthc.com/research/kulkarni-2016-novel-electrophilic-and-photoaffinity
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.